These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Lazzarino M; Orlandi E; Baldanti F; Furione M; Pagnucco G; Astori C; Arcaini L; Viglio A; Paulli M; Gerna G; Bernasconi C Br J Haematol; 1999 Dec; 107(4):877-82. PubMed ID: 10606897 [TBL] [Abstract][Full Text] [Related]
46. Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues. Larsen CR; Hansen PB; Clausen NT Am J Hematol; 2002 May; 70(1):48-50. PubMed ID: 11994981 [TBL] [Abstract][Full Text] [Related]
47. Hodgkin/Reed-Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background. Pescarmona E; Pignoloni P; Mauro FR; Cerretti R; Anselmo AP; Mandelli F; Baroni CD Virchows Arch; 2000 Aug; 437(2):129-32. PubMed ID: 10993272 [TBL] [Abstract][Full Text] [Related]
48. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576 [TBL] [Abstract][Full Text] [Related]
49. Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). Matolcsy A; Inghirami G; Knowles DM Blood; 1994 Mar; 83(5):1363-72. PubMed ID: 8118038 [TBL] [Abstract][Full Text] [Related]
50. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Maloum K; Settegrana C; Chapiro E; Cazin B; Leprêtre S; Delmer A; Leporrier M; Dreyfus B; Tournilhac O; Mahe B; Nguyen-Khac F; Lesty C; Davi F; Merle-Béral H Ann Hematol; 2009 Dec; 88(12):1215-21. PubMed ID: 19340428 [TBL] [Abstract][Full Text] [Related]
51. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223 [TBL] [Abstract][Full Text] [Related]
52. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide]. Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794 [TBL] [Abstract][Full Text] [Related]
53. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369 [TBL] [Abstract][Full Text] [Related]
54. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621 [TBL] [Abstract][Full Text] [Related]